Abstract
The introduction of novel agents, characterized by favorable toxicity profiles and higher manageability compared to conventional drugs employed in the past, has considerably changed the treatment paradigm for multiple myeloma. Continuous therapy currently represents the standard approach for myeloma patients both at diagnosis and at relapse. In younger patients, long-term maintenance after autologous transplantation significantly improved progression-free survival and overall survival compared to observation. Also in transplant-ineligible patients, continuous treatment with combinations of newer agents and maintenance treatment following a more intense induction phase proved to be superior as compared to fixed-duration therapy. Maintenance and continuous therapy at diagnosis have shown to deepen responses and suppress minimal residual disease. At relapse, continuous therapy allowed better disease control over time. This review covers the main evidence supporting the use of continuous therapy in multiple myeloma as well as the open issues, such as the optimal agents to be used and the optimal candidates for receiving them.
Article PDF
Avoid common mistakes on your manuscript.
References
Howlader, N, Noone, A, Krapcho, M, et al. SEER cancer statistics review, 1975–2014, Bethesda: National Cancer Institute; 2017. https://seer.cancer.gov/csr/1975_2014/.
Kumar, SK, Rajkumar, SV, Dispenzieri, A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111;2516–20.
Shustik, C, Belch, A, Robinson, S, et al. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol 2007;136;203–11.
Berenson, JR, Crowley, JJ, Grogan, TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99; 3163–8.
Myeloma Trialists’ Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113; 1020–34.
Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 2000;11;1427–36.
Gay, F, Jackson, G, Rosiñol, L, et al. Maintenance treatment and survival in patients with myeloma. A systematic review and network meta-analysis. JAMA Oncol 2018;4;1389–97.
Salvini, M, D’Agostino, M, Bonello, F, et al. Determining treatment intensity in elderly patients with multiple myeloma. Expert Rev Anticancer Ther 2018;18;917–30.
Stewart, AK, Rajkumar, SV, Dimopoulos, MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372;142–52.
Stewart, AK, Siegel, D, Ludwig, H, et al. Overall survival (OS) of patients with relapsed/refractory multiple myeloma (RRMM) treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd): final analysis from the randomized phase 3 ASPIRE trial. Blood 2017;130;743 [ASH 2017 59th Annual Meeting].
Dimopoulos, MA, Oriol, A, Nahi, H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;375;1319–31.
Dimopoulos, MA, White, DJ, Benboubker, L, et al. Daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of POLLUX. Blood 2017;130l;739 [ASH 2017 59th Annual Meeting].
Bahlis, N, Dimopoulos, MA, White, DJ, et al. Three-year follow up of the phase 3 pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in relapsed or refractory multiple myeloma (RRMM). Blood 132;1996 [ASH 2018 60th Meeting].
Palumbo, A, Chanan-Khan, A, Weisel, K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016;375;754–66.
Attal, M, Harousseau, J-L, Leyvraz, S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108;3289–94.
Morgan, GJ, Gregory, WM, Davies, FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012;119; 7–15.
Spencer, A, Prince, HM, Roberts, AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009;27;1788–93.
Ludwig, H, Durie, BGM, McCarthy, P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012;119; 3003–15.
Stewart, AK, Trudel, S, Bahlis, NJ, et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood 2013;121; 1517–23.
Attal, M, Lauwers-Cances, V, Marit, G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366;1782–1791.
Palumbo, A, Cavallo, F, Gay, F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014;371;895–905.
McCarthy, PL, Owzar, K, Hofmeister, CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366;1770–81.
McCarthy, PL, Holstein, SA, Petrucci, MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 2017;35:3279–89.
Jackson, GH, Davies, FE, Pawlyn, C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2019;20; 57–73.
Gay, F, Oliva, S, Petrucci, MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol 2015;16;1617–1629.
Sonneveld, P, Schmidt-Wolf, IGH, van der Holt, B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012;30;2946–55.
Goldschmidt, H, Lokhorst, HM, Mai, EK, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia 2018;32;383–90.
Rosiñol, L, Oriol, A, Teruel, AI, et al. Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. Leukemia 2017;31;1922–27.
Landgren, O, Sonneveld, P, Jakubowiak, A, et al. Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia 33;2121–43. Epub ahead of print 24 July 2019.
Gay, F, Cerrato, C, Scalabrini, DR, et al. Carfilzomib-lenalidomide-dexamethasone (KRd) induction-autologous transplant (ASCT)-Krd consolidation Vs KRd 12 cycles Vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction-ASCT-KCd consolidation: analysis of the randomized FORTE trial in newly di. Blood 2018;132;121 [ASH 2018 60th Meeting].
Korde, N, Mastey, D, Mailankody, S, et al. MRD-response driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone. Blood 2018;132;1983–83.
Evaluation, iNduction, consolidation and maintenance treatment with isatuximab, carfilzomib, LEnalidomide and dexamethasone. Clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT03104842 (accessed August 29, 2019).
Dimopoulos, MA, Gay, F, Schjesvold, F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2019;393;253–64.
Kumar, SK, Berdeja, JG, Niesvizky, R, et al. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia 2019;33;1736–46.
Moreau, P, Attal, M, Hulin, C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019;394;29–38.
Thomas, SK, Shah, JJ, Morphey, AN, et al. Updated results of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous stem cell transplant (AuSCT) in patients (Pts) with multiple myeloma (MM). Blood 2018;132;1982 [ASH 2018 60th Meeting].
Palumbo, A, Bringhen, S, Liberati, AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized controlled trial. Blood 2008;112;3107–14.
Palumbo, A, Bringhen, S, Caravita, T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367;825–31.
Zweegman, S, van der Holt, B, Mellqvist, U-H, et al. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood 2016;127;1109–16.
Stewart, AK, Jacobus, S, Fonseca, R, et al. Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood 2015;126;1294–1301.
Palumbo, A, Hajek, R, Delforge, M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366;1759–69.
Dimopoulos, MA, Petrucci, MT, Foa’ R, et al. Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of ‘progression-free survival 2’ as a clinical trial end-point. Haematologica 2015;100;e328–30.
Benboubker, L, Dimopoulos, MA, Dispenzieri, A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014;371;906–17.
Facon, T, Dimopoulos, MA, Dispenzieri, A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 2018;131;301–10.
Larocca, A, Salvini, M, De Paoli,L,et al. Efficacy and feasibility of dose/schedule-adjusted Rd-R Vs. continuous Rd in elderly and intermediate-fit newly diagnosed multiple myeloma (NDMM) patients: RV-MM-PI-0752 phase III randomized study.Blood 2018;132;305 [ASH 2018 60th Meeting].
San Miguel, JF Schlag, RK Huageva, NK, et al.Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359;906–17.
Palumbo, A, Bringhen, S, Rossi, D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010;28;5101–09.
Palumbo, A, Bringhen, S, Larocca, A, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol 2014;32; 634–40.
Mateos, M-V, Oriol, A, Martínez-López, J, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 2012;120;2581–8.
Bringhen, S, Petrucci, MT, Larocca, A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood 2014;124;63–69.
Bringhen, S, D’Agostino, M, De Paoli, L, et al. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. Leukemia 2018;32; 979–85.
Bringhen, S, Mina, R, Petrucci, MT, et al. Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. Haematologica 2019;104;1640–47.
Leleu, X, Fouquet, G, Richez, V, et al. Carfilzomib weekly plus melphalan and prednisone in newly diagnosed transplant-ineligible multiple myeloma (IFM 2012–03): a phase I trial. Clin Cancer Res 2019;25;4224–30.
Dimopoulos, MA, Grosicki, S, Jędrzejczak, WW, et al. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Eur J Cancer 2019;106;89–98.
San-Miguel, JF, Echeveste Gutierrez, M-A, Špicka, I, et al. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. Haematologica 2018;103;1518–26.
Mateos, M-V, Dimopoulos, MA, Cavo, M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 2018;378;518–28.
Facon, T, Kumar, S, Plesner, T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019;380;2104–15.
Dimopoulos,MA, Chen,C,Spencer, A, et al.Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23;2147–2152.
San Miguel,J, Weisel, K, Moreau, P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14;1055–66.
Dimopoulos, MA, Palumbo, A, Corradini, P, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood 2016;128;497–503.
Richardson, PG, Oriol, A, Beksac, M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol 2019;20;781–94.
Shah, JJ, Stadtmauer, EA, Abonour, R, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood 2015;126;2284–90.
Dimopoulos, MA, Moreau, P, Palumbo, A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016;17;27–38.
Moreau, P, Masszi, T, Grzasko, N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;374;1621–34.
Lonial, S,Weiss, BM, Usmani, SZ,et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet (London, England) 2016;387;1551–60.
Richardson, PG, Attal, M, Rajkumar, SV, et al. A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/ refractory multiple myeloma (RRMM). J Clin Oncol 2019; 37;8004 [ASCO 2019 Annual Meeting].
Lonial, S, Dimopoulos, M, Palumbo, A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015;373;621–31.
Dimopoulos, MA, Lonial, S, Betts, KA, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer 2018;124;4032–43.
D’Agostino, M, De Paoli,L,Conticello, C, et al. Continuous therapy in standard-and high-risk newly-diagnosed multiple myeloma: a pooled analysis of 2 phase III trials. Crit Rev Oncol Hematol 2018;132;9–16.
Richardson, PG, Holstein, SA, Schlossman, RL, et al. Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. Expert Opin Pharmacother 2017;18;1975–1985.
Gambella, M, Omedé, P, Spada, S, et al. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: a pooled analysis. Cancer 2019;125;750–760.
Jackson, G, Davies, FE, Pawlyn, C, et al. Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the Myeloma XI trial. Blood 2017;130;436 [ASH 2017 59th Meeting].
Sonneveld, P, Avet-Loiseau, H, Lonial, S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016;127;2955–62.
van Beurden-Tan, CHYFranken, MG, Blommestein, HM, et al. Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma. J Clin Oncol 2017;35;1312–19.
Mahindra, A, Raval, G, Mehta, P, et al. New cancers after auto-transplantations for multiple myeloma. Biol Blood Marrow Transplant 2015;21;738–45.
Bringhen, S, Milan, A, D’Agostino, M, et al. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib a consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. J Intern Med 2019;286;63–74.
Kumar S, Harrison S, Cavo M, et al. A phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. European Hematology Association (EHA) Open Access Library 2019;273254 (Abstract #LB2601, EHA 2019 24th Congress) https://library.ehaweb.org/eha/2019/24th/273254/shaji.kumar.a.phase.3.study.of.venetoclax.or.placebo.in.combination.with.html.
Vogl, DT, Dingli, D, Cornell, RF, et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol 2018;36; 859–66.
Moreau, P, Mateos, M-V, Berenson, JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol 2018;19; 953–64.
Mateos, M-V, Nahi, H, Legiec, W, et al. Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma: COLUMBA. HemaSphere 2019;3;364 [Abstract #S823, EHA 2019 24th Congress].
Amsler, IG, Jeker, B, Mansouri Taleghani, B, et al. Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma. Leuk Lymphoma 2019;60;511–14.
Mian, I, Milton, DR, Shah, N, et al. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer 2016;122;3831–37.
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review under responsibility of the International Academy for Clinical Hematology
Data availability statement: The data that support the findings of this study are available from the corresponding author, upon reasonable request.
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Bonello, F., Cetani, G., Bertamini, L. et al. Moving Toward Continuous Therapy in Multiple Myeloma. Clin Hematol Int 1, 189–200 (2019). https://doi.org/10.2991/chi.d.191101.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.d.191101.001